Tag:
Cancer Vaccines
Latest Headlines
Latest Headlines
Germany's cost watchdog decides Valeant's Provenge has added benefit after all
In January, Germany's cost watchdog decided that Dendreon's--now Valeant's--Provenge had no added benefit for men with metastatic prostate cancer. But now, it's changing its tune.
Cancer vaccine maker Aduro files for $86M IPO
Aduro Biotech is the latest to try its hand at an IPO, and it laid out its case for an $86 million IPO last week.
Gates Foundation puts $52M behind CureVac, following Sanofi, Boehringer's lead
The Bill & Melinda Gates Foundation announced this week it's betting on CureVac, a move both Sanofi and Boehringer Ingelheim made last year, committing to an mRNA technology designed to make vaccines less expensive and easier to make.
Bristol-Myers bets $1B on Bavarian Nordic cancer vaccine
After a handful of large-scale monotherapy flops for cancer vaccines, many companies now think pairing them up as part of immunotherapy combos might be the way to go. And immuno-oncology pioneer Bristol-Myers Squibb just made a big bet that that's the case.
Aduro, BMS cancer vaccine combo to start Phase II
In another step forward for cancer vaccine combos, Aduro Biotech announced Thursday that an investigator-led Phase II trial of its GVAX and CRS-207 for pancreatic cancer with Opdivo, Bristol-Myers Squibb's PD-1 drug, would begin.
Valeant touts PhII Provenge data following Dendreon buy
Valeant only just picked up Provenge and other assets from bankrupt Dendreon, but it's already trumpeting positive preliminary data for the flailing cancer vaccine. On Wednesday, it announced Phase II results showing that the immune response from Provenge continues two years after biochemically recurrent prostate cancer patients complete treatment.
Combo of Bavarian Nordic's Prostvac and BMS' Yervoy yields promising PhI results
On Tuesday, Bavarian Nordic announced positive survival data from a Phase I combination study of its active prostate cancer immunotherapy candidate Prostvac and Bristol-Myers Squibb's Yervoy (ipilimumab), an immune checkpoint inhibitor.
Advaxis nets $23M in financing for cancer vaccine development
Advaxis is pushing full steam ahead to test its cancer vaccine candidates in immunotherapy combos, and it just scored another $23 million to help its hopefuls through the clinic.
Advaxis inks pact with Incyte to test cervical cancer vaccine combo
Advaxis, on a partnering spree after joining with Merck and AstraZeneca to test its cancer vaccine candidates in immunotherapy combos, has teamed up with Incyte to trial one of its prospects in cervical cancer.
UPDATED: Valeant grabs Provenge and other Dendreon assets with raised $400M bid
It's official: Valeant will be the new owner of Dendreon's Provenge.
- « first
- ‹ previous
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- …
- next ›
- last »
